Identifying immune markers to predict Lyme disease outcomes
Unlocking serology’s secrets: harnessing novel immune biomarkers to predict Lyme disease progression and recovery
This study is looking at how certain immune markers in the blood can help predict whether people with Lyme disease will get better or continue to have symptoms after treatment, using a new technology to get clearer results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10876386 on NIH RePORTER |
What this research studies
This research investigates how specific immune biomarkers can predict the progression and recovery of Lyme disease, which affects a significant number of patients annually. By analyzing various antibody types in the blood of Lyme disease patients, the study aims to identify a unique immune profile that distinguishes those who will recover from those who may experience persistent symptoms after antibiotic treatment. The researchers have developed a novel technology called FLIP to enhance the profiling of these antibodies, providing a more detailed understanding of the immune response to Lyme disease. This approach could lead to better predictive tools for managing patient care and treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Lyme disease who are undergoing or have completed antibiotic treatment.
Not a fit: Patients with Lyme disease who do not receive antibiotic treatment or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a reliable method for predicting recovery from Lyme disease, allowing for more personalized treatment plans.
How similar studies have performed: Previous research has shown promise in identifying immune markers for other diseases, suggesting that this approach could yield valuable insights for Lyme disease as well.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Tal, Michal Caspi — Massachusetts Institute of Technology
- Study coordinator: Tal, Michal Caspi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.